Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of
therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration
of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.